Fierce Biotech1 min read
savePepGen’s stock doubles as midphase muscle dystrophy data wow analysts
PepGen’s phase 2 myotonic dystrophy type 1 data have met analysts’ best-case scenario, causing the biotech’s share price to more than double.
PepGen’s phase 2 myotonic dystrophy type 1 data have met analysts’ best-case scenario, causing the biotech’s share price to more than double.
comments(0)
5-min edit window · permanent after that